Commodore Capital LP Cogent Biosciences, Inc. Transaction History
Commodore Capital LP
- $1.18 Billion
- Q3 2024
A detailed history of Commodore Capital LP transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Commodore Capital LP holds 7,539,930 shares of COGT stock, worth $60.5 Million. This represents 6.92% of its overall portfolio holdings.
Number of Shares
7,539,930
Previous 9,738,000
22.57%
Holding current value
$60.5 Million
Previous $82.1 Million
0.8%
% of portfolio
6.92%
Previous 7.36%
Shares
13 transactions
Others Institutions Holding COGT
# of Institutions
172Shares Held
114MCall Options Held
56.7KPut Options Held
40.4K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.5MShares$84.1 Million0.31% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.24MShares$74.2 Million8.19% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$58.5 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$55.9 Million9.76% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA6.23MShares$50 Million10.93% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $528M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...